ArticleJournal of clinical medicine2019
Effect of Lipid-Testing Interval on Stoke Risk among Newly Diagnosed Dyslipidemia Patients Initiated on Statins.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
(1) Background: Although current guidelines recommend regular lipid testing for dyslipidemia patients, the effectiveness of regular lipid profile monitoring in clinical outcomes is unclear. (2) Methods: We assessed 64,664 newly diagnosed dyslipidemia patients from the Korean National Health Insurance Service Health Screening Cohort from 2003-2011 For lipid-testing frequency from all admission and outpatient records for 3 years after diagnosis. Participants were followed until 31 December 2015 for stroke. We used Cox regression analysis to determine the adjusted hazard ratio (aHR) for stroke according to lipid-testing interval. (3) Results: Compared to patients with lipid-testing intervals of ≤6 months, patients with >6 to ≤12 (aHR 1.32, 95% confidence interval (CI) 1.08-1.61), >12 to ≤18 (aHR 1.48, 95% CI 1.20-1.82), and >18 (aHR 1.54, 95% CI 1.25-1.90) month testing intervals had elevated risk of total stroke (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.